News release excerpt provided by AtriCure.
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its AtriClip™ products, which includes the AtriClip™ Standard and the AtriClip Pro™ devices.
“We are excited to bring the AtriClip to Japan,” said Mike Carrel, President and CEO of AtriCure. “This is an important milestone for our growth prospects in the Japanese market, and we are thrilled that we can offer our LAA products to Japanese customers and patients. We see a great opportunity in the Japanese market for this solution, and are looking forward to the launch.”
Click here to read the complete release.
Originally published January 19, 2016.